Response of Diabetic Papillopathy to Intravitreal Bevacizumab

Diabetic papillopathy is an uncommon hyperemic optic disc swelling that occurs in patients with long-standing diabetes, is typically self-resolving with minimal effect on vision, and is likely ischemic in origin. The purpose of the current report is to document the response of diabetic papillopathy...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Dhibi, Hassan, Khan, Arif O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162739/
https://www.ncbi.nlm.nih.gov/pubmed/21887082
http://dx.doi.org/10.4103/0974-9233.84056
_version_ 1782210859382079488
author Al-Dhibi, Hassan
Khan, Arif O.
author_facet Al-Dhibi, Hassan
Khan, Arif O.
author_sort Al-Dhibi, Hassan
collection PubMed
description Diabetic papillopathy is an uncommon hyperemic optic disc swelling that occurs in patients with long-standing diabetes, is typically self-resolving with minimal effect on vision, and is likely ischemic in origin. The purpose of the current report is to document the response of diabetic papillopathy to intravitreal injection of bevacizumab (Avastin, Genentech Inc, San Francisco, California, USA), a humanized monoclonal antibody to vascular endothelial growth factor.
format Online
Article
Text
id pubmed-3162739
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-31627392011-09-01 Response of Diabetic Papillopathy to Intravitreal Bevacizumab Al-Dhibi, Hassan Khan, Arif O. Middle East Afr J Ophthalmol Case Report Diabetic papillopathy is an uncommon hyperemic optic disc swelling that occurs in patients with long-standing diabetes, is typically self-resolving with minimal effect on vision, and is likely ischemic in origin. The purpose of the current report is to document the response of diabetic papillopathy to intravitreal injection of bevacizumab (Avastin, Genentech Inc, San Francisco, California, USA), a humanized monoclonal antibody to vascular endothelial growth factor. Medknow Publications 2011 /pmc/articles/PMC3162739/ /pubmed/21887082 http://dx.doi.org/10.4103/0974-9233.84056 Text en Copyright: © Middle East African Journal of Ophthalmology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Al-Dhibi, Hassan
Khan, Arif O.
Response of Diabetic Papillopathy to Intravitreal Bevacizumab
title Response of Diabetic Papillopathy to Intravitreal Bevacizumab
title_full Response of Diabetic Papillopathy to Intravitreal Bevacizumab
title_fullStr Response of Diabetic Papillopathy to Intravitreal Bevacizumab
title_full_unstemmed Response of Diabetic Papillopathy to Intravitreal Bevacizumab
title_short Response of Diabetic Papillopathy to Intravitreal Bevacizumab
title_sort response of diabetic papillopathy to intravitreal bevacizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162739/
https://www.ncbi.nlm.nih.gov/pubmed/21887082
http://dx.doi.org/10.4103/0974-9233.84056
work_keys_str_mv AT aldhibihassan responseofdiabeticpapillopathytointravitrealbevacizumab
AT khanarifo responseofdiabeticpapillopathytointravitrealbevacizumab